News Releases

Sep 13, 2021
Lyra Therapeutics Appoints Jason Cavalier as Chief Financial Officer
Seasoned investment banking executive brings extensive finance, partnering and M&A experience to the role WATERTOWN, Mass., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise,
Additional Formats
Sep 09, 2021
Lyra Therapeutics Announces Publication of Preclinical Pharmacokinetics and Drug Release characterization for XTreo™ Technology Platform in the American Journal of Rhinology & Allergy
Results demonstrate XTreo ™ technology platform provides targeted and sustained dosing of anti-inflammatory medication Outcomes supported advancing into clinical development for LYRA’s first indication, Chronic Rhinosinusitis, with lead product candidate, LYR-210, currently poised to enter Phase 3
Additional Formats
Jul 12, 2021
Lyra Therapeutics to Present at Upcoming Virtual Healthcare Conference
WATERTOWN, Mass. , July 12, 2021 (GLOBE NEWSWIRE) -- Lyra Therapeutics , Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other
Additional Formats
Displaying 1 - 10 of 21
Print Page
Email Alerts
RSS Feeds
Contact IR
Search
Back to Top